Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells.
The human pregnane X receptor (hPXR) regulates the expression of critical drug metabolism enzymes. One of such enzymes, cytochrome P450 3A4 (CYP3A4), plays critical roles in drug metabolism in hepatocytes that are either quiescent or passing through the cell cycle. It has been well established that the expression of P450, such as CYP3A4, is markedly reduced during liver development or regeneration. Numerous studies have implicated cellular signaling pathways in modulating the functions of nuclear receptors, including hPXR. Here we report that inhibition of cyclin-dependent kinases (Cdks) by kenpaullone and roscovitine (two small molecule inhibitors of Cdks that we identified in a screen for compounds that activate hPXR) leads to activation of hPXR-mediated CYP3A4 gene expression in HepG2 human liver carcinoma cells. Consistent with this finding, activation of Cdk2 attenuates the activation of CYP3A4 gene expression. In vitro kinase assays revealed that Cdk2 directly phosphorylates hPXR. A phosphomimetic mutation of a putative Cdk phosphorylation site, Ser(350), significantly impairs the function of hPXR, whereas a phosphorylation-deficient mutation confers resistance to Cdk2. Using HepG2 that has been stably transfected with hPXR and the CYP3A4-luciferase reporter, enriched in different phases of the cell cycle, we found that hPXR-mediated CYP3A4 expression is greatly reduced in the S phase. Our results indicate for the first time that Cdk2 negatively regulates the activity of hPXR, and suggest an important role for Cdk2 in regulating hPXR activity and CYP3A4 expression in hepatocytes passing through the cell cycle, such as those in fetal or regenerating adult liver.
Lin
Wenwei
W
Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Wu
Jing
J
Dong
Hanqing
H
Bouck
David
D
Zeng
Fu-Yue
FY
Chen
Taosheng
T
D001552:Benzazepines / Q000494:pharmacology; D002453:Cell Cycle / Q000187:drug effects / Q000235:genetics; D045744:Cell Line, Tumor; D051357:Cyclin-Dependent Kinase 2 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D051544:Cytochrome P-450 CYP3A / Q000096:biosynthesis* / Q000235:genetics; D004789:Enzyme Activation / Q000187:drug effects / Q000235:genetics; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000235:genetics; D022781:Hepatocytes / Q000201:enzymology; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D008113:Liver Neoplasms / Q000201:enzymology* / Q000235:genetics; D009154:Mutation; D010766:Phosphorylation / Q000187:drug effects / Q000235:genetics; D000077297:Pregnane X Receptor; D011987:Receptors, Steroid / Q000378:metabolism*; D012038:Regeneration / Q000187:drug effects / Q000235:genetics; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics
D001552:Benzazepines; D007211:Indoles; D000077297:Pregnane X Receptor; D011987:Receptors, Steroid; C119620:kenpaullone; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; C495894:CDK2 protein, human; D051357:Cyclin-Dependent Kinase 2
Mol Pharmacol. 2007 Oct;72(4):1045-53
17636047
Drug Metab Dispos. 2002 Jul;30(7):795-804
12065438
Mol Cell Biol. 1994 Mar;14(3):1544-52
8114692
J Cell Physiol. 2007 Nov;213(2):286-300
17559071
Cancer Res. 2007 Nov 1;67(21):10361-7
17974979
J Hepatol. 1998 Apr;28(4):700-8
9566840
Cancer Res. 1999 Jan 1;59(1):213-8
9892209
Cell Res. 2005 Oct;15(10):785-95
16246268
J Pharmacol Exp Ther. 2006 Feb;316(2):822-9
16214878
Steroids. 2007 Feb;72(2):202-9
17207508
Mol Pharmacol. 1999 Dec;56(6):1329-39
10570062
Biochem Biophys Res Commun. 2005 May 13;330(3):722-30
15809057
Genes Dev. 1998 Oct 15;12(20):3195-205
9784494
Science. 1997 Apr 4;276(5309):60-6
9082986
Mol Cell Biol. 2005 Jan;25(1):264-77
15601848
Biochim Biophys Acta. 2005 Dec 15;1746(2):85-94
16297466
Curr Drug Metab. 2008 May;9(4):310-22
18473749
J Biol Chem. 2002 Aug 16;277(33):29719-29
12055183
Science. 2006 Oct 13;314(5797):294-7
17038621
J Biomol Screen. 2004 Sep;9(6):533-40
15452340
J Pharmacol Exp Ther. 1998 Feb;284(2):760-7
9454825
Hepatology. 2006 Feb;43(2 Suppl 1):S45-53
16447274
Cancer. 2007 Mar 1;109(5):957-65
17279585
Eur J Biochem. 1997 Jan 15;243(1-2):527-36
9030781
Mol Cell Biol. 2000 Jun;20(12):4188-98
10825184
Mol Biol Cell. 2002 Jun;13(6):1977-2000
12058064
Curr Drug Metab. 2006 May;7(4):375-88
16724927
J Pharmacol Exp Ther. 2005 Feb;312(2):849-56
15459237
Cancer Res. 2000 Apr 15;60(8):2132-5
10786674
Biochem Pharmacol. 2005 Mar 1;69(5):867-73
15710363
Oncogene. 2007 Jul 5;26(31):4469-77
17297466
Methods Enzymol. 2005;400:598-618
16399373
Cell. 1990 May 18;61(4):549-51
2188729
J Biochem Mol Toxicol. 2007;21(4):169-75
17936930
Clin Pharmacol Ther. 2007 Apr;81(4):510-6
17301735
Steroids. 2007 Mar;72(3):231-46
17284330
Mol Cell Biol. 2005 Apr;25(8):2885-98
15798179
Curr Opin Chem Biol. 2008 Aug;12(4):418-26
18662801
Cancer Res. 2007 Jul 15;67(14):6685-90
17638878
Cell. 1998 Jan 9;92(1):73-82
9489701
Cancer Res. 1999 Jun 1;59(11):2566-9
10363974